The model for patients with CHB (combining serum miR-122, serum miR-222, platelet count and ALP), and the model for patients with CHC (combining hepatic miR-122, hepatic miR-224, platelet count, ALT and albumin) were able to discriminate patients with F3-F4 from those with F1-F2. This evidence concerns the gene GPT and cryohydrocytosis.